Related by context. All words. (Click for frequent words.) 76 metastatic cancer 76 metastases 76 metastatic prostate cancer 74 distant metastases 73 tumor recurrence 73 metastatic 71 metastatic breast cancer 70 liver metastases 70 distant metastasis 69 malignancies 68 brain metastases 68 NSCLC 68 tumors 68 carcinoma 68 metastatic RCC 67 malignancy 67 HER2 positive breast cancer 67 renal cell carcinoma 67 bone metastases 66 disease progression 66 adjuvant therapy 65 advanced NSCLC 65 gastric cancer 65 bone metastasis 65 unresectable 65 hepatocellular carcinoma 65 neoadjuvant therapy 64 neuroendocrine tumors 64 lymph node involvement 64 HER2 positive 64 pancreatic cancers 64 lymph node metastases 64 prostate cancers 64 chemoradiotherapy 64 colorectal cancer 64 locoregional 64 neoadjuvant chemotherapy 64 metastasis 64 metastatic melanoma 64 metastatic lesions 64 lung tumors 64 tumor shrinkage 64 recurrent prostate cancer 64 micrometastases 63 carcinomas 63 follicular lymphoma 63 metastatic tumors 63 cancers 63 biochemical recurrence 63 pancreatic adenocarcinoma 63 solid tumors 63 glioblastomas 63 adenocarcinoma 63 EBRT 63 CaP 63 metastatic renal cell carcinoma 62 sarcoma 62 stage IIIB 62 recurrent NSCLC 62 preoperative chemotherapy 62 prostate cancer CRPC 62 metastatic malignant melanoma 62 epithelial tumors 62 medullary thyroid cancer 62 HER2 negative 62 lung metastases 62 GISTs 62 pancreatic NET 62 melanoma 62 ovarian cancer 62 PCa 62 chemoradiation 62 metastatic pancreatic cancer 61 metastatic colorectal cancer 61 endometrial cancers 61 soft tissue sarcomas 61 metastatic cancers 61 glioblastoma 61 adjuvant radiation 61 advanced adenomas 61 bladder cancers 61 androgen deprivation 61 cystectomy 61 metastatic lung cancer 61 IV NSCLC 61 colorectal cancers 61 adenomas 61 melanomas 61 basal cell carcinoma BCC 61 adenoma 61 castration resistant prostate cancer 61 gastric cancers 61 renal tumors 61 localized prostate cancer 61 prostate cancer CaP 61 metastatic NSCLC 61 breast cancers 61 sarcomas 61 squamous cell carcinoma 61 trastuzumab 61 mRCC 61 tumor 60 pCR 60 prostate adenocarcinoma 60 metastatic colon cancer 60 PSADT 60 CMV disease 60 adjuvant radiotherapy 60 breast tumors 60 breast carcinoma 60 HNSCC 60 breast cancer recurrence 60 differentiated thyroid 60 ovarian cancers 60 fallopian tube carcinoma 60 tumor progression 60 axillary dissection 60 cytoreductive surgery 60 fibrosis 60 hepatocellular carcinoma HCC 60 invasive carcinoma 60 neoplasia 59 adjuvant therapies 59 resected 59 colorectal liver metastases 59 prostate cancer 59 malignant pleural mesothelioma 59 palliation 59 HER2 positive metastatic breast 59 grade dysplasia 59 dysplasia 59 hormone refractory prostate cancer 59 osteosarcomas 59 acute myelogenous leukemia AML 59 adjuvant chemotherapy 59 liver metastasis 59 heavily pretreated 59 locoregional recurrence 59 Carcinoma 59 superficial bladder cancer 59 metastatic bladder 59 HRPC 59 lung cancers 59 neoplasm 59 neoadjuvant treatment 59 Metastatic 59 colorectal cancer CRC 59 squamous cell cancer 59 bortezomib 59 precursor lesions 59 adenomatous polyps 59 esophageal cancers 59 contralateral breast 59 lymph node metastasis 59 DMARD 59 lymph nodes 59 gastric adenocarcinoma 59 BRAF mutation 58 node metastases 58 gastrointestinal stromal tumor GIST 58 grade gliomas 58 malignant growths 58 cell lung cancer 58 HCV infection 58 imatinib therapy 58 hepatic metastases 58 clinically localized prostate 58 contralateral breast cancer 58 resectable 58 heavily pretreated patients 58 androgen deprivation therapy 58 peritoneal cancer 58 osteosarcoma 58 lobular carcinoma 58 unresectable tumors 58 adenocarcinomas 58 lymphadenectomy 58 hormonal therapies 58 gastrointestinal stromal tumors 58 IV melanoma 58 malignant lesions 58 radical nephrectomy 58 HCV infected 58 EGFR mutations 58 anaplastic 58 lung cancer 58 cholangiocarcinoma 58 lymphomas 58 sorafenib 58 cervical carcinoma 58 TACE 58 hormonal therapy 58 gastrointestinal cancers 58 metastatic gastric 58 breast carcinomas 58 lesions 58 metastatic GIST 58 colon cancer 58 multiple myeloma 58 stage IIIA 58 GIST tumors 58 endometrial cancer 58 cisplatin chemotherapy 58 gemcitabine 58 HSCT 58 ovarian carcinoma 58 ascites 58 leukemia AML 58 premalignant 58 operable breast cancer 58 Barrett esophagus 58 serous ovarian cancer 58 carcinoid tumors 58 metastatic basal cell 57 liver cancer 57 lymph node dissection 57 pulmonary metastases 57 tumor resection 57 pleural mesothelioma 57 neoplasms 57 cisplatin 57 basal cell carcinomas 57 invasive breast cancer 57 bladder cancer 57 EGFR mutation 57 ovarian tumors 57 ALND 57 docetaxel 57 anthracycline taxane 57 Hepatocellular Carcinoma HCC 57 cetuximab 57 HER2 positive tumors 57 unresectable stage 57 epithelial ovarian 57 lung metastasis 57 endometrial hyperplasia 57 histologically confirmed 57 colorectal tumors 57 zoledronic acid 57 BRCA mutations 57 cytotoxic chemotherapy 57 hormone receptor positive 57 axillary lymph nodes 57 Median survival 57 astrocytoma 57 relapsed SCLC 57 biliary tract cancer 57 EGFR inhibitors 57 squamous cell carcinomas 57 prognostic variables 57 cervical lesions 57 renal cell carcinomas 57 resistant ovarian cancer 57 papillary 57 lymph node 57 nodal metastases 57 nasopharyngeal carcinoma 57 myelodysplastic syndrome MDS 57 taxane therapy 57 HBeAg negative 57 advanced adenoma 57 lymphadenopathy 57 revascularization procedures 57 uveal melanoma 57 gastrointestinal stromal tumor 57 sentinel node 57 rectal cancer 57 castrate resistant 57 hepatocellular cancer 57 prior chemotherapy regimens 57 lymphoma 57 seminoma 57 FOLFOX4 57 neoadjuvant 57 atypia 57 recurrences 57 cytoreduction 57 Metastatic breast cancer 57 urothelial carcinoma 56 carcinoid cancer 56 CLL 56 CMV infection 56 advanced unresectable 56 lupus nephritis 56 gefitinib 56 peritoneal carcinomatosis 56 vinorelbine 56 pancreatic carcinoma 56 recurrent ovarian cancer 56 prostate cancer HRPC 56 imatinib 56 rectal carcinoma 56 chemotherapeutic regimens 56 GvHD 56 SLNB 56 free survival PFS 56 carcinoid 56 adenomatous 56 cell carcinoma 56 situ CIS 56 axillary node dissection 56 curable cancers 56 metastatic kidney 56 complete remissions 56 non squamous NSCLC 56 atypical hyperplasia 56 squamous cell 56 standard chemotherapy regimens 56 colon cancers 56 postoperative chemotherapy 56 Adjuvant chemotherapy 56 prostate carcinoma 56 rectal cancers 56 colorectal carcinoma 56 indolent NHL 56 acute leukemias 56 PAOD 56 epithelial ovarian cancer 56 malignant melanoma 56 recurrent GBM 56 carboplatin paclitaxel 56 underwent resection 56 lung nodules 56 vandetanib 56 intestinal metaplasia 56 evaluable patients 56 fallopian tube cancers 56 renal carcinoma 56 malignant neoplasms 56 hormone refractory 56 DIPG 56 tamoxifen therapy 56 T#I mutation 56 atherosclerotic disease 56 precancerous lesions 56 metastatic HER2 positive 56 nonmelanoma skin cancers 56 CIN3 56 KRAS mutation 56 radical prostatectomy 56 HER2 overexpression 56 recurrent glioblastoma multiforme 56 pancreatic cancer 56 curative resection 56 gastroesophageal junction 56 myocardial ischemia 56 histologic 56 thromboembolic events 55 renal transplantation 55 skeletal metastases 55 lymphocytosis 55 cutaneous squamous cell carcinoma 55 intravesical therapy 55 liver fibrosis 55 HER2 + 55 dasatinib 55 SHPT 55 ependymoma 55 acute GvHD 55 pre cancerous lesions 55 grade glioma 55 squamous cell cancers 55 grade cervical intraepithelial 55 HER2 positive cancers 55 GIST 55 transitional cell carcinoma 55 breast cancer 55 SCCHN 55 nonalcoholic steatohepatitis NASH 55 nonmetastatic 55 chemotherapy 55 histological subtype 55 bevacizumab 55 metachronous 55 paroxysmal AF 55 lymph node removal 55 BCG refractory 55 squamous cell carcinoma SCC 55 pT3 55 relapsed ovarian cancer 55 cytotoxic therapy 55 completely resected 55 bronchogenic carcinoma 55 colorectal adenomas 55 erlotinib 55 sunitinib 55 basal cell carcinoma 55 chemotherapy regimens 55 mucinous 55 cancer 55 myelofibrosis 55 ALCL 55 pT2 55 axillary lymph node 55 tumors GIST 55 IV metastatic melanoma 55 remission induction 55 metastatic melanomas 55 axillary node 55 vertebral fracture 55 tyrosine kinase inhibitors 55 leiomyosarcoma 55 extracapsular extension 55 neoplastic lesions 55 meningiomas 55 Hurthle cell 55 endometrial carcinoma 55 T2DM 55 biochemical relapse 55 hypercalcemia 55 taxane chemotherapy 55 sentinel nodes 55 nonsmall cell lung cancer 55 DLBCL 55 TNF antagonist 55 sentinel lymph node biopsy 55 varices 55 antiplatelet therapy 55 EUS FNA 55 lymphoma CTCL 55 co morbidities 55 metastatic relapsed 55 5-FU/LV 55 prostate tumors 55 HER2 55 anti angiogenic therapy 55 leukemia ALL 55 thyroid nodules 55 recurrent glioblastoma 55 bladder tumors 55 NMIBC 55 histologies 55 nephrectomy 55 radiotherapy 55 sarcomatoid 55 oropharyngeal cancer 55 ADPKD 55 chemotherapeutic agents 55 recurrent metastatic 55 retroperitoneal 55 HBV infection 55 papillary renal cell carcinoma 55 urothelial bladder cancer 55 MGUS 55 mitoxantrone 55 micrometastasis 55 pre malignant lesions 55 gastrointestinal stromal tumors GIST 55 Bezielle 55 pelvic lymph nodes 55 chronic HBV infection 55 ductal breast cancer 55 chlorambucil 54 pancreatic neuroendocrine tumors 54 FDG PET 54 NAFLD 54 reintervention 54 lymphatic tissue 54 invasive bladder 54 microalbuminuria 54 IIIB NSCLC 54 histologically 54 radical prostatectomy RP 54 benign polyps 54 prostate cancer PCa 54 gastric carcinoma 54 mycophenolate mofetil 54 Glioblastoma Multiforme 54 refractory CTCL 54 complete cytogenetic 54 metastatic colorectal 54 dacarbazine DTIC 54 hormone deprivation 54 chemotherapy cisplatin 54 pancreatic tumors 54 pericardial effusion 54 nodal metastasis 54 hematologic malignancies 54 carcinoid tumor 54 febrile neutropenia 54 KRAS mutations occur 54 Doxil ® 54 sentinel node biopsy 54 systemic scleroderma 54 recurrent ovarian 54 PCNSL 54 liver resection 54 platinum refractory 54 hyperoxaluria 54 benign lesions 54 ipsilateral breast 54 mesotheliomas 54 GVHD 54 situ LCIS 54 chemoembolization 54 breast lesions 54 neuroblastomas 54 non metastatic osteosarcoma 54 epirubicin 54 squamous cell histology 54 medically inoperable 54 soft tissue sarcoma 54 chondrosarcoma 54 NF1 54 HPV infection 54 malignant neoplasm 54 proximal colon 54 radiation therapy 54 cytogenetic responses 54 topotecan 54 prostate cancer mCRPC 54 thymic carcinoma 54 toxicities 54 urothelial cancer 54 breast cancer subtypes 54 FOLFOX 54 DMARDs 54 chronic HCV 54 premalignant lesions 54 axillary nodes 54 medulloblastoma 54 ErbB2 positive 54 HCV 54 papillary thyroid cancer 54 anastrozole 54 thymoma 54 mTOR inhibitors 54 antiviral therapy 54 sorafenib Nexavar 54 testicular cancers 54 NSCL cancer 54 cervical lymph nodes 54 tumor histology 54 B CLL 54 neovascular AMD 54 radioiodine therapy 54 R0 resection 54 capecitabine 54 idiopathic pulmonary fibrosis IPF 54 EGFR expressing 54 carcinoids 54 prognostic indicator 54 systolic dysfunction 54 uterine cancers 54 metastatic squamous cell carcinoma 54 locoregional disease 54 leukaemias 54 refractory NSCLC 54 systemic lupus erythematosus 54 colorectal neoplasms 54 CTCL 54 scleroderma 54 tumor lysis syndrome 54 renal dysfunction 54 malignant mesothelioma 54 fluoropyrimidine 54 pituitary adenomas 54 external beam radiotherapy 54 mitral regurgitation 54 elevated CRP 54 cutaneous melanoma 54 esophageal adenocarcinoma 54 malignant pheochromocytoma 54 mCRC patients 54 BRCA mutation carriers 54 seminal vesicle invasion 54 HGS ETR1 54 transurethral resection 54 renal insufficiency 54 extracranial 54 relapsed AML 54 transplantation HCT 54 docetaxel chemotherapy 54 IRX 2 54 XELOX 53 response pCR 53 esophageal carcinoma 53 squamous 53 sustained virological response 53 proliferative diabetic retinopathy 53 BRCA deficient 53 stage IIIB IV 53 lung carcinomas 53 cervical intraepithelial neoplasia 53 prognostic factors 53 tumor regression 53 prostate pancreatic 53 Glioblastoma 53 cell carcinomas 53 pre cancerous polyps 53 curative therapy 53 hematologic toxicity 53 keloid 53 diabetic nephropathy 53 basal cell cancers 53 neoplasias 53 anthracyclines 53 tumor cells 53 rituximab 53 PNET 53 KRAS mutant tumors 53 indolent lymphomas 53 metastatic malignant 53 hepatocellular carcinomas 53 alveolar rhabdomyosarcoma 53 GnRH agonists 53 IGF 1R 53 tumor metastases 53 LHRH receptor positive 53 pancreatic ovarian 53 chronic GVHD 53 axitinib 53 chemotherapies 53 asymptomatic 53 colorectal 53 thyroid cancers 53 mediastinal 53 gemcitabine carboplatin 53 taxane 53 nodal dissection 53 endocrine therapies 53 minimally symptomatic 53 diabetes mellitus 53 malignant pleural mesothelioma MPM 53 clinically detectable 53 poorer prognosis 53 chronic lymphocytic leukemia CLL 53 biopsies 53 surgical resection 53 K ras mutations 53 chemotherapy regimen 53 decitabine 53 Surgical resection 53 octreotide 53 IV malignant melanoma 53 CYT# potent vascular disrupting 53 variceal bleeding 53 occult metastases 53 gemcitabine chemotherapy 53 lobular cancer 53 docetaxel Taxotere ® 53 metastatic pancreatic 53 neuroendocrine cancers 53 T1c 53 NNRTI resistance 53 colectomy 53 receptor tyrosine kinase inhibitor 53 temozolomide 53 hepatorenal syndrome 53 androgen independent 53 primary biliary cirrhosis 53 vertebral fractures 53 resection 53 antiangiogenic therapy 53 concurrent chemoradiation 53 intestinal polyps 53 carotid stenosis 53 peginterferon 53 multiple myeloma MM 53 thoracoscopic lobectomy 53 advanced hepatocellular carcinoma 53 gastric atrophy 53 graft dysfunction 53 MALT lymphoma 53 pelvic lymphadenectomy 53 Metastases 53 gastric lymphoma 53 metastatic renal cell 53 fibroadenomas 53 prostatic adenocarcinoma 53 histologic subtype 53 prostate tumor 53 paraganglioma 53 anti TNF 53 radiotherapy RT 53 bladder carcinoma 53 temsirolimus 53 biopsy 53 Acute Myelogenous Leukemia AML 53 Tavocept 53 systemic lupus erythematosus SLE 53 tumoral 53 myeloma 53 stable angina 53 estrogen receptor ER 53 cytogenetic response 53 evaluable 53 stage IIIb IV 53 malignant transformation 53 relapsed GBM 53 virologic failure 53 metastatic adenocarcinoma 53 hormone receptor negative 53 adalimumab 53 OncoVEX GM CSF 53 imatinib Gleevec 53 prostate cancer metastases 53 metastatic tumor 53 diabetes mellitus DM 53 inflammatory arthritis 53 activating mutations 53 adrenalectomy 53 5FU 53 relapsing remitting 53 complete cytogenetic response 53 neurologic progression 53 xenograft models 53 myeloproliferative diseases 53 ocular melanoma 53 colorectal cancer liver metastases 53 sustained virologic response 53 lymphocytic leukemia 53 cabazitaxel 53 ovarian lung 53 refractory multiple myeloma 53 chemo radiotherapy 53 venous thromboembolism 53 mutated KRAS gene 53 virological failure 53 chemoresistant 53 vismodegib 53 autoantibodies 53 fibrotic disease 53 MYCN amplification 53 cancer mCRC 53 hyperplasia 53 postoperative complication 53 undetectable PSA 53 malignant tumors 53 nodular melanoma 53 olaparib 53 severe neutropenia 53 estrogen receptor negative 53 Synovial sarcoma 53 reinfarction 53 squamous histology 53 leukemia CLL 53 HIV HCV coinfected 53 malignant gliomas 53 KRAS wild 53 anaplastic thyroid cancer 53 HBeAg positive patients 53 osteoporotic fractures 53 angiosarcoma 53 adenoid cystic carcinoma 53 cervical dysplasia 53 HER2 amplification 53 cell lymphomas 53 LHRH analogues 53 anti leukemic 53 estrogen receptor positive 53 prognostic markers 53 immunosuppressive regimens 53 candidemia 53 serum PSA 52 GBM tumors 52 cardiotoxicity 52 p# mutations 52 hematological cancers 52 subtrochanteric 52 postoperative pathology 52 postoperative pulmonary 52 myeloproliferative disorders 52 neoplastic 52 pheochromocytoma 52 glufosfamide 52 breast endometrial 52 anti angiogenic drugs 52 gliomas 52 eribulin mesylate 52 debulking surgery 52 nonoperative 52 pathologic 52 Circulating tumor cells 52 cachexia 52 MELD scores 52 thyroglobulin 52 liver histology 52 Xeloda 52 surgical excision 52 invasive ductal 52 Lymph node 52 postoperative morbidity 52 dacarbazine 52 esophagogastric junction 52 talactoferrin 52 HGPIN 52 biliary strictures 52 ischemic cardiomyopathy 52 melanoma lesions 52 orchiectomy 52 perioperative complications 52 therapeutic regimens 52 AA amyloidosis 52 TNFerade 52 nonmetastatic prostate cancer 52 PNH patients 52 Cristofanilli 52 irinotecan chemotherapy 52 parathyroid 52 endometriosis 52 thrombotic complications 52 EGFR 52 depsipeptide 52 endometrial 52 esophageal tumors 52 medulloblastomas 52 prospectively defined 52 DCIS 52 thyroid carcinoma 52 CD# + [002] 52 smoldering multiple myeloma 52 abnormal mammograms 52 acute aortic dissection 52 seminomas 52 atherothrombosis 52 mycosis fungoides 52 prostate TURP 52 advanced neoplasia 52 recurrent glioblastoma multiforme GBM 52 FOLFIRI 52 TTF Therapy 52 metastatic neuroendocrine tumors 52 Radical prostatectomy 52 sporadic ALS 52 squamous cell lung cancer 52 refractory AML 52 Her2 52 posaconazole 52 invasive aspergillosis 52 oesophageal 52 cyclophosphamide 52 lobular carcinomas 52 T1a 52 severe sepsis 52 FSGS 52 radiofrequency ablation RFA 52 acromegaly 52 recurrent VTE 52 CTEPH 52 intravenous bisphosphonates 52 proteinuria 52 nonsquamous histology 52 Alessandro Riva 52 periodontitis 52 nephropathy 52 colorectal adenoma 52 bowel resection 52 relapsed leukemia 52 renal disease 52 Bortezomib 52 rhabdomyosarcoma 52 situ DCIS 52 sorafenib Nexavar ® 52 gastrectomy 52 Toxicities 52 geographic atrophy 52 acute ischemic stroke 52 Wilms tumor 52 EGFR TKI 52 ventricular dysfunction 52 OMAPRO 52 TKI therapy 52 oesophageal cancer 52 prostate breast 52 virologic response 52 SBRT 52 recurrent colorectal cancer 52 exemestane 52 atherosclerotic lesions 52 T1DM 52 IMGN# 52 invasive ductal carcinoma 52 metastatic HRPC 52 aneurysm rupture 52 abiraterone 52 Tumor shrinkage 52 rebleeding 52 colorectal polyps 52 Cholangiocarcinoma 52 invasive cervical cancer 52 alvespimycin 52 endosonography 52 pancreatic tumor 52 hamartomas 52 unresectable locally advanced 52 advanced epithelial ovarian 52 refractory ovarian cancer 52 radiochemotherapy 52 colon tumors 52 androgen suppression 52 MPS IVA 52 HPV infections 52 pelvic malignancies 52 CMV infections 52 keloids 52 histologically proven 52 ductal carcinomas 52 plus gemcitabine 52 median PFS 52 paclitaxel eluting stents 52 pulmonary emboli 52 Irinotecan 52 nasopharyngeal cancer 52 secondary hyperparathyroidism 52 CLL cells 52 microvascular complications 52 allogeneic SCT 52 esophagectomy 52 glioblastoma tumors 52 ductal cancer 52 hematuria 52 androgen suppression therapy 52 visceral metastases 52 HCV genotype 52 prognostic factor 52 hematologic malignancy 52 cytoreductive nephrectomy 52 left ventricular dysfunction 52 hyperplastic polyps 52 mCRC 52 predictive biomarkers 52 catheter angiography 52 idarubicin 52 aromatase inhibitor 52 allogeneic transplantation 52 Recurrences 52 YONDELIS 52 precancerous cervical lesions 52 juvenile idiopathic arthritis 52 cystic lesions 52 laryngeal cancer 52 carboplatin 52 mitomycin 52 colorectal adenocarcinoma 52 antitumor effect 52 LHRH agonists 52 allogeneic bone marrow 52 macroalbuminuria 52 gynecological cancers 52 T#I [002] 52 tumor subtypes 52 sulfasalazine 52 axilla 52 perioperative mortality 52 myeloma cells 52 Glioblastoma multiforme GBM 52 latent TB infection 52 S. aureus infections 52 cT3 prostate cancer 52 EFAPROXYN 52 papillary RCC 52 chromosomal abnormalities 52 extranodal 52 Proxinium TM 52 cell lymphoma CTCL 52 colorectal lung 52 graft occlusion 52 progression TTP 51 gefitinib Iressa 51 B7 H3 51 bendamustine 51 BRCA2 mutations 51 taxanes 51 APOL1 51 prostatectomy 51 mucositis 51 AP# [003] 51 refractory angina 51 supratentorial 51 antihypertensive therapy 51 PSA nadir 51 diffuse gastric 51 idiopathic myelofibrosis 51 malignant lymphoma 51 lesion 51 distal colon cancer 51 metastatic castration resistant 51 hematological malignancies 51 mitoxantrone chemotherapy 51 acute myeloid leukemia 51 portal vein thrombosis 51 EGFr 51 synovial sarcoma 51 glioma 51 mediastinal lymph nodes 51 AA Amyloidosis 51 #.#ng/ml 51 tyrosine kinase inhibitors TKIs 51 partial nephrectomy 51 leukemia APL 51 liposarcoma 51 precancer 51 Renal Cell Carcinoma RCC 51 severe aortic stenosis 51 castrate resistant prostate cancer 51 unresectable liver cancer 51 relapsing MS 51 chronic periodontitis